Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 7/20 | 0.73 |
| ▸ | BAD | Q92934 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158041 | 1.00 | BCL2 (1.00) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL158040 | 1.00 | BCL2 (1.00) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL13812532 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL13982547 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL5970105 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL5970104 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL14163443 | 0.88 | KMT2A (0.78) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL13657863 | 0.87 | BCL2 (0.77) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL3426372 | 0.87 | BCL2 (0.76) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL3426376 | 0.87 | BCL2 (0.76) | BCL2MEN1KMT2AMCL1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714447-A1 | DRUG COMBINATIONS OF BCL-XL INHIBITORS FOR TREATMENT OF CANCER | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | claimed |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2026-01-08 | — | — | US | claimed |
| EP-4554613-A2 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2025-05-21 | — | — | EP | claimed |
| US-20240335539-A1 | MODULATION OF BCL-2 TO ENHANCE CHIMERIC ANTIGEN RECEPTOR CANCER IMMUNOTHERAPY EFFICACY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-10-10 | — | — | US | claimed |
| US-20240316060-A1 | LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-09-26 | — | — | US | claimed |
| CN-118488841-A | Combination of PRMT5 inhibitor and anticancer therapeutic agent | 南京再明医药有限公司 | 2024-08-13 | — | — | CN | claimed |
| EP-3703755-B1 | COMBINATION COMPRISING AT LEAST ONE SPLICEOSOME MODULATOR AND AT LEAST ONE INHIBITOR CHOSEN FROM BCL2 INHIBITORS, BCL2/BCLXL INHIBITORS, AND BCLXL INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2024-07-31 | — | — | EP | claimed |
| WO-2024133630-A1 | CHEMICALLY DISRUPTABLE MOLECULE SWITCH AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2024-06-27 | — | — | WO | claimed |
| EP-4384541-A1 | MODULATION OF BCL-2 TO ENHANCE CHIMERIC ANTIGEN RECEPTOR CANCER IMMUNOTHERAPY EFFICACY | The Trustees of the University of Pennsylvania (US) | 2024-06-19 | — | — | EP | claimed |
| EP-4384171-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | claimed |
| EP-3581660-B1 | NICHE TARGETING OF QUIESCENT CANCER STEM CELLS | UNIV CALIFORNIA (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230074759-A1 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | claimed |
| WO-2023016995-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | claimed |
| WO-2023019165-A1 | MODULATION OF BCL-2 TO ENHANCE CHIMERIC ANTIGEN RECEPTOR CANCER IMMUNOTHERAPY EFFICACY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-16 | — | — | WO | claimed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | claimed |
| US-11524009-B2 | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-12-13 | — | — | US | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| WO-2022159497-A1 | COMBINATION THERAPY SCHEDULES TO TREAT CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-28 | — | — | WO | claimed |
| CN-114786654-A | Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists | 密执安大学评议会 | 2022-07-22 | — | — | CN | claimed |
| WO-2020223609-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY (US) | 2020-11-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524009-B2 | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | BCLAF1, BCL2L10, BCOR | BCL2 11/4885MEN1 3589/4885KMT2A 1972/4885 |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | BCL3, BCL9, BCL9L | BCL2 17/4885MEN1 3293/4885KMT2A 711/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | BCL2 4/4885MEN1 4725/4885KMT2A 4222/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885MEN1 4419/4885KMT2A 2931/4885 |
| US-20230074759-A1 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | MALT1, BCL6, BCL3 | BCL2 6/4885MEN1 1304/4885KMT2A 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.